RICHTER SYNDROME
Clinical trials for RICHTER SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RICHTER SYNDROME trials appear
Sign up with your email to follow new studies for RICHTER SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise against rare blood cancer
Disease control Recruiting nowThis study tests a combination of three drugs—lisocabtagene maraleucel (a personalized cell therapy), nivolumab (an immunotherapy), and ibrutinib (a targeted pill)—in 20 adults with Richter's transformation, an aggressive form of leukemia. The goal is to see if this triple therap…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 01:49 UTC
-
New combo tackles rare, aggressive lymphoma in CLL patients
Disease control Recruiting nowThis study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can improve survival by…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 01:45 UTC
-
New hope for richter syndrome: targeted antibody combo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs for people with Richter syndrome, an aggressive lymphoma that can develop in patients with chronic lymphocytic leukemia (CLL). The treatment adds a targeted antibody called glofitamab to standard chemotherapy. The goal is to see if this…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo targets aggressive blood cancer in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—zanubrutinib and odronextamab—is safe and effective for people with Richter's transformation, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The trial enrolls 23 adults whose cancer has come back…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy targets aggressive leukemia transformation
Disease control Recruiting nowThis study tests a drug called polatuzumab vedotin combined with standard chemotherapy for people whose chronic lymphocytic leukemia has turned into a more aggressive form called Richter's transformation. About 20 adults will receive up to six treatment cycles and be monitored fo…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for rare, aggressive blood cancer: drug duo enters trial
Disease control Recruiting nowThis study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New combo therapy aims to keep lymphoma in check after transplant
Disease control Recruiting nowThis study is for people with certain types of lymphoma (B-cell or Hodgkin) that have come back or not responded well to treatment. Participants first receive a stem cell transplant using their own cells, then if their disease is stable or better, they get up to 8 doses of a targ…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated May 01, 2026 16:00 UTC